» Articles » PMID: 23644528

KDM4/JMJD2 Histone Demethylases: Epigenetic Regulators in Cancer Cells

Overview
Journal Cancer Res
Specialty Oncology
Date 2013 May 7
PMID 23644528
Citations 230
Authors
Affiliations
Soon will be listed here.
Abstract

Lysine methylation is one of the most prominent histone posttranslational modifications that regulate chromatin structure. Changes in histone lysine methylation status have been observed during cancer formation, which is thought to be a consequence of the dysregulation of histone lysine methyltransferases or the opposing demethylases. KDM4/JMJD2 proteins are demethylases that target histone H3 on lysines 9 and 36 and histone H1.4 on lysine 26. This protein family consists of three ~130-kDa proteins (KDM4A-C) and KDM4D/JMJD2D, which is half the size, lacks the double PHD and Tudor domains that are epigenome readers and present in the other KDM4 proteins, and has a different substrate specificity. Various studies have shown that KDM4A/JMJD2A, KDM4B/JMJD2B, and/or KDM4C/JMJD2C are overexpressed in breast, colorectal, lung, prostate, and other tumors and are required for efficient cancer cell growth. In part, this may be due to their ability to modulate transcription factors such as the androgen and estrogen receptor. Thus, KDM4 proteins present themselves as novel potential drug targets. Accordingly, multiple attempts are under way to develop KDM4 inhibitors, which could complement the existing arsenal of epigenetic drugs that are currently limited to DNA methyltransferases and histone deacetylases.

Citing Articles

Targeting KDM4C Prevents Heart Failure after Acute Myocardial Infarction Via Activation of SOS2.

Tan C, Chen X, Xu L, Chen J, Tu Y J Cardiovasc Transl Res. 2025; .

PMID: 39900886 DOI: 10.1007/s12265-025-10594-2.


ETV2/ER71 regulates hematovascular lineage generation and vascularization through an H3K9 demethylase, KDM4A.

Kim M, Lee R, Lee D, Song H, Ha T, Kim J iScience. 2025; 28(1):111538.

PMID: 39811655 PMC: 11732216. DOI: 10.1016/j.isci.2024.111538.


Analogue-Sensitive Inhibition of Histone Demethylases Uncovers Member-Specific Function in Ribosomal Protein Synthesis.

Kuwik J, Scott V, Chedid S, Stransky S, Hinkelman K, Kavoosi S J Am Chem Soc. 2025; 147(4):3341-3352.

PMID: 39808475 PMC: 11783601. DOI: 10.1021/jacs.4c13870.


The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications.

Duan X, Xing Z, Qiao L, Qin S, Zhao X, Gong Y Front Immunol. 2024; 15:1495221.

PMID: 39620228 PMC: 11604627. DOI: 10.3389/fimmu.2024.1495221.


Targeting N-Methyl-lysine Histone Demethylase KDM4 in Cancer: Natural Products Inhibitors as a Driving Force for Epigenetic Drug Discovery.

Cursaro I, Milioni L, Eslami K, Sirous H, Carullo G, Gemma S ChemMedChem. 2024; 20(4):e202400682.

PMID: 39498961 PMC: 11831885. DOI: 10.1002/cmdc.202400682.


References
1.
Li B, Luo C, Li H, Yang P, Zhang M, Xu H . Effects of siRNA-mediated knockdown of jumonji domain containing 2A on proliferation, migration and invasion of the human breast cancer cell line MCF-7. Exp Ther Med. 2012; 4(4):755-761. PMC: 3501409. DOI: 10.3892/etm.2012.662. View

2.
Kim T, Shin S, Berry W, Oh S, Janknecht R . The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells. J Cell Biochem. 2011; 113(4):1368-76. DOI: 10.1002/jcb.24009. View

3.
Hillringhaus L, Yue W, Rose N, Ng S, Gileadi C, Loenarz C . Structural and evolutionary basis for the dual substrate selectivity of human KDM4 histone demethylase family. J Biol Chem. 2011; 286(48):41616-41625. PMC: 3308871. DOI: 10.1074/jbc.M111.283689. View

4.
Gray S, Iglesias A, Lizcano F, Villanueva R, Camelo S, Jingu H . Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein. J Biol Chem. 2005; 280(31):28507-18. DOI: 10.1074/jbc.M413687200. View

5.
Kooistra S, Helin K . Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol. 2012; 13(5):297-311. DOI: 10.1038/nrm3327. View